GlassScriptPhysician profile
Robyn K Sato
NPI 1053405670
$4,396.04
in general payments reported to CMS, 2019-2025
34 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $828 · 2021: $1,774 · 2022: $502 · 2023: $14.91 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,292.48 | 2020-2021 | |
| Daiichi Sankyo INC. | $408.16 | 2019 | |
| Biodelivery Sciences International, INC. | $391.74 | 2019-2021 | |
| Abbvie INC. | $354.50 | 2021-2025 | Botox |
| Collegium Pharmaceutical, INC. | $330.73 | 2019-2022 | |
| Lilly USA, LLC | $250.67 | 2019-2022 | |
| Allergan, INC. | $223.12 | 2019-2020 | |
| Amgen INC. | $113.72 | 2019-2022 | |
| Medtronic, INC. | $99.67 | 2025 | Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $97.73 | 2022 | |
| Eisai INC. | $88.25 | 2020 | |
| Grt US Holding, INC. | $83.29 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.16 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.91 | 2019 | |
| Hikma Pharmaceuticals USA | $54.86 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $49.79 | 2019-2021 | |
| Sentynl Therapeutics, INC. | $40.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.97 | 2019-2020 | |
| Horizon Therapeutics Plc | $36.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.72 | 2019 | |
| Indivior INC. | $26.01 | 2020 | |
| Scilex Pharmaceuticals INC. | $23.75 | 2020 | |
| Redhill Biopharma INC. | $23.63 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $22.93 | 2021 | |
| Promius Pharma LLC | $20.14 | 2019 | |
| Bioventus LLC | $19.33 | 2019 | |
| Fidia Pharma USA INC. | $17.31 | 2020 | |
| Impel Pharmaceuticals INC. | $16.59 | 2022 | |
| Avanos Medical | $15.94 | 2019 | |
| Medtronic USA, INC. | $15.90 | 2020 | |
| Orthogenrx INC. | $15.52 | 2020 | |
| Shionogi INC | $11.65 | 2019 | |
| Vertos Medical, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Sato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.